



ASX / Media Release
17 July 2019

ShareRoot Closes Rights Issue and Notification of Undersubscriptions

The Board of ShareRoot Limited (ASX:SRO) (**Company**), is pleased to advise that:

- The Entitlement Offer closed on Friday, 12 July 2019 (**Closing Date**), raising \$509,612.07 from Eligible Shareholders of the Company.
- The shortfall under the Entitlement Offer is 444,731,041 shares (which could raise up to approximately \$444,731), which the Company can allocate and issue at the Board's discretion within 3 months of the Closing Date.
- The Company has received interest for the available shortfall shares, and will continue to keep the market informed of any updates.

The Company has accepted applications from Eligible Shareholders for 509,611,125 shares at an issue price of \$0.001, raising \$509,612.07 (before costs). This includes applications for additional shares from Eligible Shareholders, which have been accepted by the Company.

Accordingly, the shortfall under the Entitlement Offer equates to 444,731,041 shares. As disclosed in the Company's offer booklet, the directors reserve their right to allot the shortfall at their discretion within 3 months of the Closing Date. As of this announcement, the Company remains in discussions with a number of parties and brokers in relation to the available shortfall shares.

The Company would like to thank its shareholders for supporting the Entitlement Offer.

The following table sets out a summary of the outcome from the Entitlement Offer:

Description	Number of New Shares	Gross Proceeds	% of Entitlement Offer
Maximum number of shares offered under the Entitlement Offer	954,342,166	\$954,342	100%
Total applications accepted by the Company from Eligible Shareholders	509,611,125	\$509,612.07	53.4%
Remaining available shortfall	Up to 444,731,041	Up to \$444,731	46.6%

The issue of shares under the Entitlement Offer to the Eligible Shareholders will take place on Friday, 19 July 2019.

As previously announced, the funds raised will be applied as follows:

- to pay the costs of making the Entitlement Offer;
- scale the existing revenue-generating digital client services capabilities and capacity;
- complete and launch new technology products and roll out marketing campaigns;
- continue development of MediaConsent Clinical;
- re-name ShareRoot to reposition the Company within the target market; and
- the remaining balance will be used to fund ongoing working capital and strengthen the Company's balance sheet.

About ShareRoot

Under the stewardship of a new Chief Executive, Michelle Gallaher, ShareRoot is positioning itself as a major player in the global digital healthcare sector by harnessing the potential of real-world data and evidence gathered from social media to guide the development of novel therapeutics and devices, improve patient activation and lead improvements to clinical practice.

Established in 2013 and listed on the Australian Stock Exchange in late 2015, ShareRoot relocated from the United States to Australia in 2019 with the change in leadership, re-aligning the strategy to focus on health and life sciences.

ShareRoot technologies, consulting and content creation teams use social media, artificial intelligence and machine learning to support and accelerate the advancement of technologies for life and good health.

ShareRoot's goal is to utilise the vast social media networks, patient-generated content and platforms, combined with artificial intelligence, machine learning and emerging digital tools to support deeper insight and more meaningful interactions for patients, carers and healthcare providers. Our vision is to make healthcare more personal.